May 21, 2012
The majority of patients with long-bone fractures receive inadequate pain medication in the emergency department, and disparities in management exist.
Legislation recently enacted in the State of Washington to moderate opioid dosing in light of a 240% increase in deaths between 2001 and 2009 is placing physicians in the position of negotiating with patients with chronic noncancer pain to taper doses, a panel of physicians noted during the American Pain Society's 31st Annual Scientific Meeting.
At the American Pain Society's 31st Annual Scientific Meeting, study investigators presented data indicating that high dosages of oxymorphone extended-release (ER) appear to be generally well tolerated in patients with chronic noncancer pain.
"Significant, clinically meaningful improvements in spontaneous bowel movement (SBM) frequency were observed after CB-5945 treatment," stated Lee Techner, DPM, from Cubist Pharmaceuticals, Lexington, MA at the American Pain Society's 31st Annual Scientific Meeting.
At the American Pain Society's 31st Annual Scientific Meeting, Jon Levine, MD, PhD discussed recent data showing that kappa-opioids, generally observed to be less effective in providing pain relief than mu-receptor opioids, were not only equally effective in producing pain relief in a female patient population, but were also associated with a reduced incidence of adverse effects and greater overall patient satisfaction.